TRILLO ALIAGA, PAMELA
TRILLO ALIAGA, PAMELA
Universita' degli Studi di MILANO
Co-Occurring Driver Genomic Alterations in Advanced Non-Small-Cell Lung Cancer (NSCLC): A Retrospective Analysis
2024 I. Attili, R. Asnaghi, D. Vacirca, R. Adorisio, A. Rappa, A. Ranghiero, M. Lombardi, C. Corvaja, V. Fuorivia, A. Carnevale Schianca, P. Trillo Aliaga, G. Spitaleri, E. Del Signore, J. Guarize, L. Spaggiari, E. Guerini-Rocco, N. Fusco, F. De Marinis, A. Passaro
Immune-Related Adverse Event Likelihood Score Identifies “Pure” IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population
2024 L. Mazzarella, F. Giugliano, E. Nicolo, A. Esposito, E. Crimini, G. Tini, J. Uliano, C. Corti, P. D'Amico, P.T. Aliaga, C. Valenza, M. Repetto, G. Antonarelli, L. Ascione, G. Vivanet, P.P.M. Berton Giachetti, I. Minchella, C. Belli, M. Locatelli, C. Criscitiello, G. Curigliano
MET in Non-Small-Cell Lung Cancer (NSCLC): Cross ‘a Long and Winding Road’ Looking for a Target
2023 G. Spitaleri, P. Trillo Aliaga, I. Attili, E. Del Signore, C. Corvaja, C. Corti, J. Uliano, A. Passaro, F. de Marinis
Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastases
2023 P. Trillo, J. Sandoval, D. Trapani, E. Nicolò, P. Zagami, F. Giugliano, P. Tarantino, G. Vivanet, L. Ascione, A. Friedlaender, A. Esposito, C. Criscitiello, G. Curigliano
Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running?
2023 G. Spitaleri, P. Trillo Aliaga, I. Attili, E. Del Signore, C. Corvaja, C. Corti, E. Crimini, A. Passaro, F. de Marinis
Screening Programs for Breast Cancer: Toward Individualized, Risk-Adapted Strategies of Early Detection
2023 D. Trapani, J. Sandoval, P.T. Aliaga, L. Ascione, P.P. Maria Berton Giachetti, G. Curigliano, O. Ginsburg
The Immune-related adverse event (IRAE) Likelihood Score (ILS) identifies “pure” IRAEs strongly associated with outcome in a phase I-II trial population
2022 L. Mazzarella, E. Nicolò, A. Esposito, E. Crimini, G. Tini, J. Uliano, C. Corti, P. Trillo Aliaga, C. Valenza, M. Repetto, G. Antonarelli, I. Minchella, C. Belli, M. Locatelli, C. Criscitiello, G. Curigliano
Should temozolomide be used on the basis of O6-methylguanine DNA methyltransferase status in patients with advanced neuroendocrine tumors? A systematic review and meta-analysis
2021 P. Trillo Aliaga, F. Spada, G. Peveri, V. Bagnardi, C. Fumagalli, A. Laffi, M. Rubino, L. Gervaso, E. Guerini Rocco, E. Pisa, G. Curigliano, N. Fazio
Safety of covid-19 mrna vaccines in patients with cancer enrolled in early-phase clinical trials
2021 P. Trillo Aliaga, D. Trapani, J.L. Sandoval, E. Crimini, G. Antonarelli, G. Vivanet, S. Morganti, C. Corti, P. Tarantino, A. Friedlaender, C. Belli, I. Minchella, M. Locatelli, A. Esposito, C. Criscitiello, G. Curigliano